Background and objective
========================

Little information exists on long-term outcome of JDM. Furthermore, most studies have been conducted in single centres or have involved a few patients. Objective of the study is to identify predictors of a poorer long-term outcome of JDM in a multicenter cohort of patients.

Methods
=======

490 patients with JDM and disease duration \> 2 years seen in 27 centers in 5 countries (Italy, UK, Argentina, Brazil, Mexico) after 1980 were identified. Outcomes included muscle weakness (MMT), continued activity (DAS), cumulative damage (MDI), calcinosis, lipodystrophy, functional impairment (CHAQ), and health-related quality of life (HRQL) impairment (CHQ). Predictors included: continent (Europe vs. Latin America), gender, year of onset, onset age, onset type (acute vs. insidious), onset manifestations, severity of muscle/skin manifestations at onset, and course type (monocyclic, polycyclic, chronic continuous).

Results
=======

Table [1](#T1){ref-type="table"} shows significant predictors for each outcome.

  (\*At onset)         M. weak\'ss   Cont\'d activity   Damage   Funct. Impairm\'nt   HRQL Impairm\'nt
  -------------------- ------------- ------------------ -------- -------------------- ------------------
  Female sex           \+            \-                 \-       \+                   \-
  Onset after 2000     \+            \-                 \-       \-                   \-
  Onset age \< 5 yrs   \-            \-                 \-       \-                   \-
  Onset type           \-            \+                 \-       \-                   \+
  Dysphonia\*          \+            \-                 \-       \-                   \-
  Mm/skin severity\*   \-            \-                 \-       \-                   \+
  Chronic Course       \+            \+                 \+       \+                   \+

Conclusion
==========

The chronic continuous course predicted all outcomes, which highlights the critical need for treatments and treatment strategies that have the ability to better control disease activity over time.
